Companion Animal Vaccines Market Volume Analysis, Segments, Value Share and Key Trends 2016-2026
Companion animal vaccines are used to stimulate an immune response in pets such as canine, avian and feline. These vaccine products are of various types such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live vaccines are derived from disease-causing pathogens such as virus or bacteria, which have been weakend under laboratory conditions. Conjugate vaccines are an antigen or toxoid-containing preparation that is linked to polysaccharides and stimulate the immature immune system to defend against the disease-causing organism. Inactivated vaccines are made from microorganisms such as viruses and bacteria that have been killed through physical or chemical processes. Subunit vaccines, like inactivated whole-cell vaccines, do not contain live components of the pathogen. Toxoid vaccines are based on the toxin produced by certain bacteria, which is rendered harmless and used as the antigen in the vaccine to elicit an immune response. DNA vaccines are manufactured by inserting DNA into a bacterial plasmid, which functions as the vector. Recombinant vaccines are produced by genetic engineering technology and use attenuated virus or bacterium as a vector to introduce microbial DNA to the cells of the body. The global companion animal vaccines market was valued at more than US$ 2,100 Mn in 2015 and is projected to register a CAGR of 6.8% during the forecast period. The market is expected to be valued at nearly US$ 4,500 Mn by the end of 2026. Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1427
Companion animal vaccines are used to stimulate an immune response in pets such as canine, avian and feline. These vaccine products are of various types such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live vaccines are derived from disease-causing pathogens such as virus or bacteria, which have been weakend under laboratory conditions. Conjugate vaccines are an antigen or toxoid-containing preparation that is linked to polysaccharides and stimulate the immature immune system to defend against the disease-causing organism. Inactivated vaccines are made from microorganisms such as viruses and bacteria that have been killed through physical or chemical processes. Subunit vaccines, like inactivated whole-cell vaccines, do not contain live components of the pathogen. Toxoid vaccines are based on the toxin produced by certain bacteria, which is rendered harmless and used as the antigen in the vaccine to elicit an immune response. DNA vaccines are manufactured by inserting DNA into a bacterial plasmid, which functions as the vector. Recombinant vaccines are produced by genetic engineering technology and use attenuated virus or bacterium as a vector to introduce microbial DNA to the cells of the body.
The global companion animal vaccines market was valued at more than US$ 2,100 Mn in 2015 and is projected to register a CAGR of 6.8% during the forecast period. The market is expected to be valued at nearly US$ 4,500 Mn by the end of 2026.
Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1427
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Companion</strong> <strong>Animal</strong> <strong>Vaccines</strong> <strong>Market</strong><br />
Zoetis <strong>and</strong> Merck Dominate US$ 2.26 Bn <strong>Companion</strong> <strong>Animal</strong> <strong>Vaccines</strong> <strong>Market</strong><br />
Zoetis Inc. will continue to account for a leading share of the US$ 2.26 Bn (<strong>2016</strong>) global companion<br />
animal vaccine market. The pharmaceutical company accounted for over 46% share of the global market<br />
in 2015, <strong>and</strong> it is expected to maintain its numero uno position during the forecast period <strong>2016</strong>-<strong>2026</strong>.<br />
Merck & Co., Inc. <strong>and</strong> Merial, will remain the other key players in this market.<br />
The key factors that will fuel dem<strong>and</strong> for companion animal vaccines include,<br />
Increasing trend of pet humanisation in developing countries<br />
Adoption of pet vaccination programmes, such as ‘herd immunity’ <strong>and</strong> ‘One Health’<br />
Increasing emphasis on preventing <strong>and</strong> detecting avian flu<br />
Rising pet insurance rates in the U.S. <strong>and</strong> other developed countries<br />
Awareness on the benefits of preventive healthcare over reactive healthcare<br />
Collaboration among leading pharmaceutical manufacturers for research <strong>and</strong> development.<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved 4
Change language